Connetics' Verdeso Foam gets FDA approval for atopic dermatitis

By Lisa Kerner

Charlotte, N.C., Sept. 20 - The Food and Drug Administration has approved Connetics Corp.'s topical steroid Verdeso (desonide) Foam, 0.05%, for the treatment of mild-to-moderate atopic dermatitis.

The Palo Alto, Calif., pharmaceutical company expects to begin marketing Verdeso, previously referred to as Desilux, to physicians in the fourth quarter of 2006 in 50 g and 100 g trade unit sizes.

Verdeso is formulated in Connetics' proprietary VersaFoam-EF emulsion formulation, containing no ethanol and providing a moisturizing feel similar to creams and ointments.

"The low-potency corticosteroid desonide in VersaFoam-EF has been shown in our clinical trials to be safe and effective in children as young as three months of age," executive vice president of research and development Lincoln Krochmal said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.